What’s good for Canopy is good for the market
We’ve read the $CGC / $WEED Q4 quarterlies, and are here to bring you the greatest hits, including some curious reporting changes.
TSX:ACB
Quite the production: A look at Aurora’s inventory and operations
$ACB projects that they’ll be able to grow 150,000 kgs / year of high-test #cannabis. The Fundamental Hype research department had a look at how they’re doing so far.
How do you solve a problem like Aurora?
Fundamental Hype listened to the $ACB earnings call and went through the quarterlies to bring you a look at the one and only Aurora Cannabis.
Bruised up: FH reads the Harvest Moon Cannabis report on Aurora so you don’t have to
@BettingBruiser’s report on $ACB’s portfolio is a great read if you can get through it. We broke out a summary for a pre-earnings call amuse-bouche.
Organigram crushes earnings, still cheap
$OGI had a banger of a quarter and is still one of our favorite Canadian cultivators in the latest marijuana datajam.
Supply-side gamesmanship: Did Tilray just buy the connect?
$EMC & $ALEF stand to come out ahead on $TLRY’s Natura deal. But can they keep their supply?
Is Aurora Cannabis’ bid for Whistler Medical Marijuana just an opener?
$ACB’s made a $175M all-stock bid for private Whistler Medical after unloading some $TGOD. $CRON may have something to say about this before it’s over.
APH the world turns
All eyes were on $APHA Friday, as the best soap opera in the pot world arrived at the much-anticipated culmination of its latest high-drama plot arc, and payed it off in epic fashion.
The war for retail cannabis shelf space: January 2019 edition
$APHA is still at the top of the product mix, with $WEED close behind. Some big moves this month, including the rise of $TLRY retail and a new launch from $OGI.